|
|
|
|
|
| September 22, 2011 | ISSUE NUMBER 218 VOL 8 |
Regulatory
Obama Deficit Plan Sides with Over Big Pharma
The Obama Administration's cost-cutting plan has more in common with a proposal put forward by pharmacy benefits manager companies than with brand drug manufacturers, writes Ben Comer ...Read More
M&As
Deals Don't Need Science To Be A Success
But what do they need? Brian McGilligan points out some fundamental non-scientific principles to follow to secure the success of the deal ...Read More
Global
Roche Gets Tough On Greece. Who'll Be Next?
Roche’s decision to cut off the supply of its drugs to certain Greek hospitals may have been a long time coming. But is it acceptable to do elsewhere what they do in Greece? ...Read More
Patients
Evaluating Expanded Access Programs
David Vance, Senior Director of the Compliance Counsel at Noven Pharmaceuticals, talks to Pharm Exec about the birth of Expanded Access Programs and the role patient advocacy groups can play in shaping them
...Read more
Innovative Contracting
Should the US Gamble With Risk Sharing?
Is risk sharing a good idea when payers come to the table holding the best cards—leaving industry second-guessing its strategy? ...Read more |
|
|
 // Navitus Health Solutions (Madison, Wis.) announced that its Board of Directions unanimously chose Terry Seligman to be Chief Executive Officer (CEO). // SCS Healthcare Marketing (Mahwah, NJ) recruited Patrick Purcell as Vice President of Sales to lead the company's Business Development group. // Amylin Pharmaceuticals (San Diego, Calif.) has made two senior leadership promotions. Marcea Bland Lloyd, one of Amylin's Executive Officers, was promoted to the role of Senior Vice President, Chief Administrative Officer (CAO) and General Counsel. Harry Leonhardt, also an Executive Officer, was promoted to the role of Senior Vice President, Legal and Compliance, Deputy General Counsel and Corporate Secretary. //
Zafgen (Cambridge, Mass.) has appointed Dennis Kim, M.D., M.B.A., to the newly created position of Chief Medical Officer, assuming primary responsibility for its clinical development of obesity therapeutics. |
|
|
|
|
|
 |
|
|
|
 |
|
|
|
 |
|
 |
| Has your company experienced increased FDA scrutiny during the past year? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
